ResMed (RMD) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
ResMed (RMD) share price 'may have overcompensated' - Morgan Stanley
October 27, 2023 11:38 AM EDTMorgan Stanley upgraded shares of ResMed (NYSE: RMD) to Overweight from Equal-Weight, lowering the price target on the stock to $169 from $180 per share in a note to clients Friday.
Analyst Sean Laaman told investors that their deep dive analysis on the obstructive sleep apnea (OSA) market suggests the... More
